Neuronetics, Inc. (NASDAQ:STIM) Q2 2023 Earnings Conference Call August 8, 2023 8:30 PM ET Company Participants Mark Klausner - ICR Westwicke Keith Sullivan - President and Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants Margaret Kaczor - William Blair Zachary Day - Canaccord Simran Kaur - Piper Sandler Daniel Stauder - JMP Securities Operator Thank you for standing by, welcome to the Neuronetics Second Quarter 2023 Financial and Operating Results Conference Call ...

Limitations of Antidepressant Medications ieving remission (HAMD The largest prospective clinical trial of MDD ever conducted, STAR*D, showed that treatment resistance causes a patient's chance for remission to decrease with each subsequent medication attempt. STAR*D also showed discontinuation due to side effects increases with each medication attempt. | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|------------|------------------------|----------------------------------- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporation ...

Neuronetics, Inc. (NASDAQ:STIM) Q1 2023 Earnings Conference Call May 13, 2023 8:30 AM ET Company Participants Mark Klausner - ICR Westwicke Keith Sullivan - President and Chief Executive Officer Steve Furlong - Chief Financial Officer Operator Thank you for standing by, and welcome to the Neuronetics First Quarter 2023 Financial and Operating Results. [Operator Instructions] As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Mr. Mark Klausner. Plea ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporation or or ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2022 was $18.2 million, an increase of 21% compared to Q4 2021 revenue of $15 million [69] - U.S. NeuroStar Advanced Therapy System revenue was $4.6 million, up 64% from $2.8 million in the prior year [84] - U.S. treatment session revenue reached an all-time record of $12.5 million, an 11% increase over Q4 2021 [70] - Gross margins remained consistent at 76% compared to Q4 2021 [87] - Net loss for Q4 2022 was $8.3 million, compared to a net loss of $7.6 million in Q4 2021 [88] Business Line Data and Key Metrics Changes - The per click consumable segment and other segments are performing well, contributing to the anticipated 20% growth in 2023 [2] - Revenue per active site was approximately $11,500 in Q4 2022, down from approximately $12,200 in the prior year [85] - The number of treatment sessions surpassed 5.3 million across roughly 145,000 patients [67] Market Data and Key Metrics Changes - The company expects to see continued strength from local per click customers despite lower treatment session revenue from certain service providers [90] - The expansion of Medicare coverage and changes in United Health Care's policies are expected to positively impact market access [81] Company Strategy and Development Direction - The company aims to increase customer participation in NeuroStar University and co-op marketing programs to drive growth [49][51] - A focus on creating a network of accounts that follow NeuroStar best practices is planned for 2023 [15] - The company is working to simplify prior authorization processes to expand market access [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 20% growth in 2023, driven by strong performance in non-Greenbrook segments [2][39] - The company does not anticipate recessionary impacts affecting its guidance for 2023 [39] - Management acknowledged the challenges posed by the integration of Greenbrook and Success, which may lead to revenue headwinds [78] Other Important Information - The company shipped over 210 systems in 2022, bringing total systems shipped to over 2,000 [67] - The cash and cash equivalents as of December 31, 2022, were $70.3 million [89] Q&A Session Summary Question: What do you expect out of your core business in 2023? - Management expects growth to be consistent with the second half of 2022, in the 20% range [2] Question: How do you think about the capital versus disposable? - Capital is expected to be consistent with 2022, with 45 to 50 systems anticipated for the year [57] Question: What gets you to the high and low-end of the guidance range? - Management indicated that some contribution from Greenbrook is needed, but growth from other segments should suffice to meet guidance [11] Question: How do you view the impact of coverage policy updates? - Management believes the updates will expand the market and simplify access to care [24] Question: What are the key drivers of treatment session revenue? - The practice development managers and the implementation of PHQ-10s are key drivers of increased utilization [26]

TAP INTO A NEW POSSIBILITY for depression COMPANY PRESENTATION NASDAQ: STIM November 2022 Disclaimers n e u r o s t a r . c o m This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data ...

Neuronetics, Inc. (NASDAQ:STIM) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Mark Klausner - ICR Westwicke Keith Sullivan - President and Chief Executive Officer Stephen Furlong - Senior Vice President, Chief Financial Officer and Treasurer Conference Call Participants Adam Maeder - Piper Sandler Margaret Kaczor - William Blair Bill Plovanic - Canaccord Marie Thibault - BTIG Operator Good day and thank you for standing by. Welcome to the Neuronetics Report Third Quarter ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ incorporation or organization) Delaware 33-1051425 (State or other jurisdiction of (I.R.S. Employer Identification No.) (A ...